Literature DB >> 20471332

Opportunities for quality improvement in cystic fibrosis newborn screening.

Molly K Groose1, Richard Reynolds, Zhanhai Li, Philip M Farrell.   

Abstract

BACKGROUND: With the rapid implementation of cystic fibrosis (CF) newborn screening (NBS), quality improvement (QI) has become essential to identify and prevent errors. Using Process Failure Modes and Effects Analysis (PFMEA), we adapted this method to determine if it could be applied to discover and rank high priority QI opportunities.
METHODS: Site visits to three programmes were conducted, and PFMEA exercises were accomplished in Colorado, Massachusetts and Wisconsin with 23 experienced professionals. During each of these comprehensive sessions, participants identified and ranked potential failures based on severity, occurrence and detection to calculate risk priority number (RPN) values.
RESULTS: A total of 96 failure modes were generated and ranked in a list of the 20 riskiest problems that show no significant discordances by site, although there were differences by profession of the rater, particularly nurses.
CONCLUSIONS: Our results illustrate that the PFMEA method applies well to CF NBS and that steps requiring communication and information transfer are perceived to be the highest risks. The number of identified failures makes and their potential impact demonstrate considerable overall risk and a need for ongoing QI. Copyright 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20471332      PMCID: PMC2900403          DOI: 10.1016/j.jcf.2010.04.001

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  8 in total

Review 1.  Newborn screening for cystic fibrosis: an opportunity to improve care and outcomes.

Authors:  Preston W Campbell; Terry B White
Journal:  J Pediatr       Date:  2005-09       Impact factor: 4.406

2.  Misunderstanding about communication.

Authors:  Lawrence S Wissow; Lori Hamby Erby
Journal:  Arch Pediatr Adolesc Med       Date:  2008-03

3.  Guidelines for implementation of cystic fibrosis newborn screening programs: Cystic Fibrosis Foundation workshop report.

Authors:  Anne Marie Comeau; Frank J Accurso; Terry B White; Preston W Campbell; Gary Hoffman; Richard B Parad; Benjamin S Wilfond; Margaret Rosenfeld; Marci K Sontag; John Massie; Philip M Farrell; Brian P O'Sullivan
Journal:  Pediatrics       Date:  2007-02       Impact factor: 7.124

4.  Newborn screening for cystic fibrosis in Wisconsin: nine-year experience with routine trypsinogen/DNA testing.

Authors:  Michael J Rock; Gary Hoffman; Ronald H Laessig; Greg J Kopish; Thomas J Litsheim; Philip M Farrell
Journal:  J Pediatr       Date:  2005-09       Impact factor: 4.406

5.  Improving the health of patients with cystic fibrosis through newborn screening. Wisconsin Cystic Fibrosis Neonatal Screening Study Group.

Authors:  P M Farrell
Journal:  Adv Pediatr       Date:  2000

Review 6.  Newborn screening for cystic fibrosis: evaluation of benefits and risks and recommendations for state newborn screening programs.

Authors:  Scott D Grosse; Coleen A Boyle; Jeffrey R Botkin; Anne Marie Comeau; Martin Kharrazi; Margaret Rosenfeld; Benjamin S Wilfond
Journal:  MMWR Recomm Rep       Date:  2004-10-15

7.  Assessment of parental understanding by pediatric residents during counseling after newborn genetic screening.

Authors:  Michael H Farrell; Pramita Kuruvilla
Journal:  Arch Pediatr Adolesc Med       Date:  2008-03

8.  European best practice guidelines for cystic fibrosis neonatal screening.

Authors:  Carlo Castellani; Kevin W Southern; Keith Brownlee; Jeannette Dankert Roelse; Alistair Duff; Michael Farrell; Anil Mehta; Anne Munck; Rodney Pollitt; Isabelle Sermet-Gaudelus; Bridget Wilcken; Manfred Ballmann; Carlo Corbetta; Isabelle de Monestrol; Philip Farrell; Maria Feilcke; Claude Férec; Silvia Gartner; Kevin Gaskin; Jutta Hammermann; Nataliya Kashirskaya; Gerard Loeber; Milan Macek; Gita Mehta; Andreas Reiman; Paolo Rizzotti; Alec Sammon; Dorota Sands; Alan Smyth; Olaf Sommerburg; Toni Torresani; Georges Travert; Annette Vernooij; Stuart Elborn
Journal:  J Cyst Fibros       Date:  2009-02-26       Impact factor: 5.482

  8 in total
  5 in total

1.  Growth and pulmonary outcomes during the first 2 y of life of breastfed and formula-fed infants diagnosed with cystic fibrosis through the Wisconsin Routine Newborn Screening Program.

Authors:  Sarah A Jadin; Grace S Wu; Zhumin Zhang; Suzanne M Shoff; Benjamin M Tippets; Philip M Farrell; Tami Miller; Michael J Rock; Hara Levy; HuiChuan J Lai
Journal:  Am J Clin Nutr       Date:  2011-03-23       Impact factor: 7.045

2.  Assessment of Parental Understanding of Positive Newborn Screening Results and Carrier Status for Cystic Fibrosis with the use of a Short Educational Video.

Authors:  R Temme; A Gruber; M Johnson; L Read; Y Lu; J McNamara
Journal:  J Genet Couns       Date:  2014-09-19       Impact factor: 2.537

3.  Factors accounting for a missed diagnosis of cystic fibrosis after newborn screening.

Authors:  Michael J Rock; Hara Levy; Christina Zaleski; Philip M Farrell
Journal:  Pediatr Pulmonol       Date:  2011-08-24

4.  Informing parents about positive newborn screen results: parents' recommendations.

Authors:  Natalie Salm; Elena Yetter; Audrey Tluczek
Journal:  J Child Health Care       Date:  2012-09-14       Impact factor: 1.979

5.  Primary care providers' experiences notifying parents of cystic fibrosis newborn screening results.

Authors:  Caitlin Finan; Samya Z Nasr; Erin Rothwell; Beth A Tarini
Journal:  Clin Pediatr (Phila)       Date:  2014-08-06       Impact factor: 1.168

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.